Longevity · NNMT inhibitor · Compounded 503A
5-Amino-1MQ: NNMT inhibition for fat loss and NAD+ preservation.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is overexpressed in obesity and aging, where it depletes the body's methyl-donor and NAD+ precursor pool. Inhibiting it has produced fat loss, muscle preservation, and metabolic improvement in preclinical models.
What 5-Amino-1MQ is
5-Amino-1MQ is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT). It is not a peptide — it is a small organic molecule — but it is included in the kindr longevity catalog because it is prescribed through the same compounded-pharmacy pathway and addresses overlapping metabolic and longevity goals.
NNMT is an enzyme that methylates nicotinamide (a precursor in the NAD+ salvage pathway), producing 1-methylnicotinamide (1-MNA) and consuming S-adenosylmethionine (SAM, the body's main methyl donor) in the process. When NNMT is overactive — as it is in obesity, aging adipose tissue, and several cancers — it depletes both SAM and the precursor pool that feeds NAD+ synthesis.
Inhibiting NNMT preserves both methyl-donor capacity and the nicotinamide pool, indirectly supporting NAD+ synthesis. In animal models of obesity and aging, NNMT inhibition produces fat loss, preserved muscle mass, and improved metabolic parameters — the basis for current clinical interest.
How it works
5-Amino-1MQ selectively inhibits NNMT activity. With NNMT blocked, nicotinamide is preserved in the salvage pathway feeding NAD+ synthesis, and SAM is preserved as a methyl donor for hundreds of other reactions throughout the cell.
In adipose tissue, NNMT inhibition shifts the metabolic balance toward fat oxidation. In skeletal muscle, it supports protein synthesis and helps preserve lean mass during caloric restriction — a key feature for patients losing weight on GLP-1s who want to minimize lean-mass loss.
Mechanistically, the most replicated finding is preserved NAD+ pools and improved mitochondrial function in tissues where NNMT was previously overactive. This makes 5-amino-1MQ complementary to direct NAD+ precursors like NMN and NR — they support NAD+ synthesis from different angles.
What patients use it for
Fat metabolism
The most-cited preclinical finding — NNMT inhibition shifts adipose tissue metabolism toward fat oxidation, with reductions in fat mass in obese mouse models.
Muscle preservation
Particularly relevant for patients losing weight rapidly (e.g. on GLP-1s) where lean-mass loss is a concern. NNMT inhibition supports muscle protein synthesis even in caloric deficit.
NAD+ pool support
By preserving the nicotinamide precursor pool, 5-amino-1MQ indirectly supports NAD+ synthesis — complementary to direct NMN / NR / NAD+ injection protocols.
Methyl-donor preservation
By sparing SAM consumption, NNMT inhibition supports methylation capacity across the cell — including DNA methylation, neurotransmitter synthesis, and phospholipid biosynthesis.
Evidence summary
Kraus D et al. (Nature, 2014) demonstrated that NNMT is overexpressed in obese adipose tissue and that NNMT knockdown protects against diet-induced obesity in mice — the foundational paper that launched current clinical interest.
Neelakantan H et al. (Biochemical Pharmacology, 2018) characterized 5-amino-1MQ as a selective small-molecule NNMT inhibitor with favorable preclinical pharmacology and demonstrated fat-loss effects in mouse models of diet-induced obesity.
Direct human clinical trial data for 5-amino-1MQ is early. The clinical use exceeds the published RCT base. Honest framing: the preclinical rationale is strong; the human outcome RCTs are not yet published. Discuss with your physician.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Most commonly prescribed as an oral capsule, typically 50–150 mg daily — though dose and duration vary by protocol.
Often used in 8–12-week courses, especially in conjunction with GLP-1 therapy (semaglutide / tirzepatide) where the muscle-preservation rationale is most clinically relevant.
Compounded 5-amino-1MQ from licensed 503A pharmacies is the typical U.S. dispensing pathway.
Safety and contraindications
Generally well-tolerated in early clinical experience. The published human safety database is small. Mild GI symptoms have been reported in some patients.
Contraindications: pregnancy, active malignancy (relative — discuss with physician), significant liver disease.
Off-label use under physician supervision through a licensed 503A pharmacy. Not FDA-approved.
Who it's typically considered for
- Patients on GLP-1 therapy (semaglutide / tirzepatide) wanting to minimize lean-mass loss during rapid weight reduction
- Adults with metabolic dysfunction and a longevity-axis orientation
- Patients already on or considering NAD+ protocols (5-amino-1MQ and direct NAD+ support are complementary)
- Patients comfortable with the honest evidence framing — strong preclinical case, early human outcome data
Frequently asked questions
Is 5-amino-1MQ a peptide?
No — 5-amino-1MQ is a small organic molecule, not a peptide. It is included in the kindr longevity catalog because it is prescribed through the same compounded-pharmacy pathway and addresses overlapping metabolic and longevity goals.
Is 5-amino-1MQ FDA-approved?
No. 5-amino-1MQ is not FDA-approved for any indication. Compounded 5-amino-1MQ is prepared by licensed 503A pharmacies under physician prescription for off-label use.
How does 5-amino-1MQ relate to NAD+ therapy?
Complementary. NAD+ precursors (NMN, NR, direct NAD+ injection) provide raw material for NAD+ synthesis. 5-amino-1MQ preserves the nicotinamide precursor pool by blocking its consumption through NNMT. They address NAD+ pools from opposite sides of the equation.
Should I take 5-amino-1MQ with semaglutide?
This is one of its most common clinical uses — to mitigate lean-mass loss during rapid weight reduction on GLP-1s. The preclinical rationale is strong; many physicians offer the combination based on the muscle-preservation mechanism.
How long until I see changes?
Body composition changes typically appear over 8–12 weeks. The preclinical fat-loss effect is modest and most clinically relevant as a complement to lifestyle change and other metabolic interventions — not as a standalone fat-loss drug.
Is 5-amino-1MQ safe long-term?
The long-term human safety profile is not fully characterized. Shorter-course protocols with reassessment are the norm. Be skeptical of any provider recommending indefinite use without periodic labs.
Can women in menopause use 5-amino-1MQ?
Yes. Some of the metabolic shifts in perimenopause and menopause — increased visceral adiposity, declining lean mass, methylation demand — are exactly what NNMT inhibition is hypothesized to address.
Sources
- Kraus D et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature (2014). — www.nature.com/articles/nature13198
- Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology (2018). — pubmed.ncbi.nlm.nih.gov/30053442
- Pissios P. Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme. Trends in Endocrinology & Metabolism (2017). — pubmed.ncbi.nlm.nih.gov/28291578
- Hong S et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nature Medicine (2015). — www.nature.com/articles/nm.3882
Considering 5-Amino-1MQ?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.